JP2025526402A5 - - Google Patents

Info

Publication number
JP2025526402A5
JP2025526402A5 JP2025504350A JP2025504350A JP2025526402A5 JP 2025526402 A5 JP2025526402 A5 JP 2025526402A5 JP 2025504350 A JP2025504350 A JP 2025504350A JP 2025504350 A JP2025504350 A JP 2025504350A JP 2025526402 A5 JP2025526402 A5 JP 2025526402A5
Authority
JP
Japan
Prior art keywords
approximately
weeks
administered
doses
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025504350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025526402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/071103 external-priority patent/WO2024026395A1/en
Publication of JP2025526402A publication Critical patent/JP2025526402A/ja
Publication of JP2025526402A5 publication Critical patent/JP2025526402A5/ja
Pending legal-status Critical Current

Links

JP2025504350A 2022-07-27 2023-07-27 潰瘍性大腸炎及びクローン病治療のための抗ｔｌ１ａ抗体 Pending JP2025526402A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263369591P 2022-07-27 2022-07-27
US63/369,591 2022-07-27
US202263387786P 2022-12-16 2022-12-16
US63/387,786 2022-12-16
PCT/US2023/071103 WO2024026395A1 (en) 2022-07-27 2023-07-27 Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease

Publications (2)

Publication Number Publication Date
JP2025526402A JP2025526402A (ja) 2025-08-13
JP2025526402A5 true JP2025526402A5 (https=) 2025-09-05

Family

ID=87747839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025504350A Pending JP2025526402A (ja) 2022-07-27 2023-07-27 潰瘍性大腸炎及びクローン病治療のための抗ｔｌ１ａ抗体

Country Status (12)

Country Link
US (1) US20250270336A1 (https=)
EP (1) EP4562040A1 (https=)
JP (1) JP2025526402A (https=)
KR (1) KR20250044336A (https=)
CN (1) CN119894931A (https=)
AU (1) AU2023314783A1 (https=)
CA (1) CA3262839A1 (https=)
CL (1) CL2025000202A1 (https=)
IL (1) IL318428A (https=)
MA (1) MA71621A (https=)
MX (1) MX2025001041A (https=)
WO (1) WO2024026395A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
US9683998B2 (en) * 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
PL3774897T3 (pl) * 2018-04-30 2024-01-29 Cedars-Sinai Medical Center Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi
AU2020275413A1 (en) * 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
WO2021034639A1 (en) * 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. High concentration anti-c5 formulations
BR112022025667A2 (pt) 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a

Similar Documents

Publication Publication Date Title
JP6283665B2 (ja) Ｇｄ２陽性癌を治療するための方法
JP2014533279A5 (https=)
JP2013166765A5 (https=)
JP2008507555A5 (https=)
JP7703513B2 (ja) 抗ガレクチン９抗体と化学療法剤の組合せがん治療
JP2021130668A (ja) 多発性骨髄腫（ｍｍ）の処置
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
JP2022531408A5 (https=)
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
WO2023217268A1 (zh) 抗tim-3抗体与抗pd-1抗体的药物组合
US20230058779A1 (en) Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof
JP2025515092A5 (https=)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2020521777A (ja) 抗ｃｄ１９抗体とベネトクラクスとの組み合わせ治療のための治療パラダイム
JP2025526402A5 (https=)
JP2024521105A5 (https=)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
WO2021213523A1 (zh) 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
WO2024183622A1 (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
CN121079314A (zh) 用于组合疗法的方法和组合物
TW202428254A (zh) 用於治療晚期實性瘤之組成物及方法
JP2024532744A (ja) Ｔ１ｇｉｔアンタゴニスト、ｐｄ－１アンタゴニスト、及び（１又は複数の）化学療法剤を含む治療的組合せ
JP2021528399A5 (https=)
JP2024531220A (ja) Ｔｉｇｉｔアンタゴニスト、ｐｄ－１アンタゴニスト、及びレンバチニブを含む治療薬の組み合わせ